Plasma microRNA signatures in drug-Naïve Romanian adolescents with First-Episode Psychosis
Clinical Scorecard: Circulating microRNA Profiles in Drug-Naïve Romanian Adolescents Experiencing First-Episode Psychosis
At a Glance
Category Detail
Condition First-Episode Psychosis (FEP) Key Mechanisms Circulating microRNAs (miRNAs) as potential biomarkers Target Population Drug-naïve Romanian adolescents aged 15-18 years Care Setting Psychiatric assessment and research
Key Highlights
Study involved 14 adolescents: 7 with FEP and 7 healthy controls Assessment of 179 miRNAs using qRT-PCR 21 miRNAs showed significant level differences between FEP and controls miR-125a-5p, miR-23b-3p, and miR-146a-5p correlated negatively with symptom severity Unique miRNA profile observed in treatment-naïve adolescents Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical assessment using PANSS, HAM-D, and YMRS scales Management
No specific management recommendations provided; focus on biomarker identification Monitoring & Follow-up
Monitor symptom severity in relation to miRNA levels Risks
Consider individual differences and symptom overlap in assessment Patient & Prescribing Data
Drug-naïve adolescents with first-episode psychosis
No treatment insights provided; study focuses on biomarker potential
Clinical Best Practices
Account for age, treatment status, and environmental variables in interpretation of miRNA modifications Related Resources & Content
